Clearside Biomedical Inc

NASDAQ:CLSD

0.81

+0.01 (+0.78%)

4:56:19 PM EDT: $0.82 +0.01 (+0.95%)

Market Cap (Intraday)	63.61M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$0.5 Million
Adjusted EPS	-$0.10

See more estimates

10-Day MA	N/A
50-Day MA	N/A
200-Day MA	N/A

See more pivots

Clearside Biomedical Inc Stock, NASDAQ:CLSD

900 North Point Parkway, Suite 200, Alpharetta, Georgia 30005

United States of America

Phone: +1.678.270.3631

Number of Employees: 30

http://www.clearsidebio.com

Description

Clearside Biomedical, Inc. is a biopharmaceutical company that delivers therapies to the back of the eye through the suprachoroidal space. Its SCS microinjector enables a simple, repeatable, in-office procedure to deliver treatments directly to the macula, retina, or choroid, potentially helping to preserve and improve vision in patients with serious eye diseases. Its pipeline includes CLS-AX, an Integrin Inhibitor, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.